[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346571-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-346571-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","evaluating-high-risk-breast-cancer-surveillance-outcomes-in-brca-mutation-carriers","Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers","","Long-term outcomes of breast cancer surveillance for BRCA mutation carriers remain limited, particularly among Asian populations with low uptake of preventive surgery. A retrospective cohort study followed 722 female BRCA1/BRCA2 carriers in Hong Kong from 2007 to 2024. Most underwent structured high-risk surveillance using biannual examinations plus alternating 6-month breast MRI and mammography or tomosynthesis with ultrasonography. Surveillance detected 64 cancers across 4,398 imaging sessions, mainly stage 0–I and node-negative, with uncommon interval cancers and low breast cancer-specific mortality.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluating-high-risk-breast-cancer-surveillance-outcomes-in-brca-mutation-carriers/346571/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluating-high-risk-breast-cancer-surveillance-outcomes-in-brca-mutation-carriers/346571.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study design and cohort size?","Question",{"text":63,"@type":64},"The study used a retrospective cohort design, enrolling 722 female BRCA1/BRCA2 mutation carriers in Hong Kong between 2007 and 2024.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What surveillance approach did most carriers receive?",{"text":68,"@type":64},"Most carriers received structured high-risk surveillance, combining biannual clinical breast examinations with alternating 6-month breast MRI and mammography or digital breast tomosynthesis with ultrasonography.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings of the surveillance outcomes?",{"text":72,"@type":64},"Surveillance detected 64 breast cancers with a detection rate of 1.5%, with most cancers diagnosed at stage 0 or I and most being node-negative; interval cancers were uncommon.",{"name":74,"@type":61,"acceptedAnswer":75},"How did prophylactic mastectomy uptake and mortality results compare?",{"text":76,"@type":64},"Risk-reducing mastectomy was performed by 12.5% of carriers, breast cancer-specific mortality was 2.4%, and most deaths were due to ovarian cancer; longer-term follow-up was recommended.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},346571,1790380945,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":122,"preview_page_count":33,"preview_urls":149},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Breast Cancer (2026) 33:407–414  \n[https://doi.org/10.1007/s12282-026-01822-x](https://doi.org/10.1007/s12282-026-01822-x)  \nORIGINAL ARTICLE  \nEvaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers  \nYuk-Kwan Chang1 · Wing-Pan Luk2 · Ling-Hiu Fung2 · Ava Kwong3  \nReceived: 27 October 2025 / Accepted: 31 December 2025 / Published online: 3 February 2026 © The Author(s) 2026  \nAbstract  \nBackground Long-term outcome on breast cancer surveillance in BRCA mutation carriers are limited, especially in Asian populations where uptake of preventive surgery is low.  \nMethods We conducted a retrospective cohort study of 722 female BRCA1 and BRCA2 mutation carriers enrolled between January 2007 and December 2024 in the Hong Kong Hereditary Breast Cancer Family Registry. Of these, 702 (97.2%) underwent structured high-risk surveillance comprising biannual clinical breast examination and alternating 6-monthly breast magnetic resonance imaging and mammography or digital breast tomosynthesis with ultrasonography. The outcomes were breast cancer detection rate, stage, nodal status, interval cancer occurrence, and breast cancer–specific mortality. Results Risk-reducing mastectomy was undertaken by 90 out of 722 carriers (12.5%) . Surveillance detected 64 breast cancers during 4,398 imaging sessions (detection rate 1.5%). Most cancers (89.1%) were diagnosed at stage 0 or I, and 95.3% were node-negative. Interval cancers were uncommon. Among 304 carriers initially free of breast cancer who later developed the disease (n = 26), no breast cancer–specific death occurred. Overall, breast cancer–specific mortality in the cohort was 2.4%, with most deaths due to ovarian cancer with a median follow-up of 39.1 months (range, 6-212.3) . Longer term follow-up is warranted.  \nConclusions In this first Asian surveillance cohort of BRCA mutation carriers, prophylactic mastectomy uptake was low, yet structured screening enabled early-stage detection and minimal interval cancer. Surveillance should be considered as a key management strategy, with preventive surgery options individualized and cost-effectiveness evaluated.  \nKeywords BRCA mutation · Hereditary breast cancer · Surveillance · Asia · Risk-reducing mastectomy  \nBackground  \nGermline BRCA1 and BRCA2 pathogenic variants are associated with a significantly increased lifetime breast cancer risk of 50–85%[1], as well as elevated risks for ovarian, pancreatic, and prostate cancers [2, 3] . Among those with  \n􀀍 Ava Kwong  \navakwong@hku.hk; [akwong@asiabreastregistry.com](akwong@asiabreastregistry.com)  \n1 Department of Surgery, Queen Mary Hospital and Tung Wah Hospital, Hong Kong, Hong Kong S.A.R., China  \n2 Research Department, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, China  \n3 Division of Breast Surgery, Department of Surgery, School of Clinical Medicine, University of Hong Kong, Hong Kong Hereditary Breast Cancer Family Registry, Breast Surgery Centre and Cancer Genetics Centre, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, China  \nprior breast cancer, the risks of metachronous cancers are also substantially increased, especially in BRCA1 mutation and those with young-onset disease [4, 5] .  \nBreast cancer preventive strategies for BRCA mutation carriers include life-style modifications, surgery, chemoprevention, and enhanced surveillance. Risk-reducing surgery is the most effective and cost-efficient option compared to surveillance or chemoprevention [6] . A meta-analysis of 21 studies revealed that risk-reducing mastectomy (RRM) significantly reduces cancer risk by more than 90%[7], thoughthe mortality benefit remains inconsistent [4, 8] . In an international study of more than 1600 women with BRCA pathogenic variants, RRM reduces the risk of breast cancer, and the probability of dying from breast cancer within 15 years after RRM was 0.95%[9] Recent studies suggest survival benefits in selected patients. A 2024 multicenter study of 5,290 y","cbCaigwizVaVYdjL","https://ap.wps.com/l/cbCaigwizVaVYdjL","pdf",704786,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the study design and cohort size?\",\"answer\":\"The study used a retrospective cohort design, enrolling 722 female BRCA1/BRCA2 mutation carriers in Hong Kong between 2007 and 2024.\"},{\"question\":\"What surveillance approach did most carriers receive?\",\"answer\":\"Most carriers received structured high-risk surveillance, combining biannual clinical breast examinations with alternating 6-month breast MRI and mammography or digital breast tomosynthesis with ultrasonography.\"},{\"question\":\"What were the key findings of the surveillance outcomes?\",\"answer\":\"Surveillance detected 64 breast cancers with a detection rate of 1.5%, with most cancers diagnosed at stage 0 or I and most being node-negative; interval cancers were uncommon.\"},{\"question\":\"How did prophylactic mastectomy uptake and mortality results compare?\",\"answer\":\"Risk-reducing mastectomy was performed by 12.5% of carriers, breast cancer-specific mortality was 2.4%, and most deaths were due to ovarian cancer; longer-term follow-up was recommended.\"}]","Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers | PDF",1790062003,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74a7895e08353787a65ee7a766d0be2a.webp",983,1305,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f43b25294fb372857e423377fa87f41.webp",982,1304,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/449ae7e48b3a00d7d5a19105351458c0.webp",981,1303,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60ecb3383e3b51c6cf1632fcf3de3ab5.webp",980,1301]